The federal government is appealing an injunction that stops the National Institutes of Health from capping reimbursement to universities for research-related expenses, sparing Pittsburgh’s biggest research institutions from funding cuts, for now.
U.S. Attorney Leah B. Foley notified the Massachusetts U.S. District Court on Monday that the government was appealing a preliminary injunction issued Saturday that stops the NIH from capping reimbursement for ancillary research expenses at 15% of the total award. The appeal of U.S. District Judge Angel Kelley’s order was filed with the United States Court of Appeals for the First Circuit.
Universities negotiate individually for indirect costs related to NIH research grants to cover such things as lab equipment, maintenance and utilities. The University of Pittsburgh receives 59% or 59 cents for every dollar of direct research award; Carnegie Mellon receives 51.8% or about 52 cents for every NIH dollar awarded.
The temporary injunction is an early step in a lawsuit filed Feb. 10 by three plaintiff groups against the NIH by 22 attorneys general — not including Pennsylvania — and various medical and university associations.
If the lower ratio is ultimately enacted, Pitt stands to lose about $182 million annually based on its total NIH awards in 2024 of $661.2 million.
Carnegie Mellon University, which received $37.2 million in NIH grants last year, stands to lose $8.5 million annually.
Read More
“CMU cannot cover the funding gap itself that would result from the reduction of the indirect cost rate,” university Vice President of Research Theresa S. Mayer wrote in plaintiffs’ supporting documents. “While CMU maintains an endowment, it is neither feasible nor sustainable for CMU funds or other revenue sources to offset shortfalls in indirect cost ratio.”
Judge Kelley agreed in issuing the permanent injunction.
“The imminent risk of halting life-saving clinical trials, disrupting the development of innovative medical research and treatment and shuttering of research facilities, without regard for current patient care, warranted the issuance of a nationwide temporary restraining order,” she wrote.
The government has said the cap would free up $4 billion, which would be plowed back into funding direct research.
In 2023, the NIH issued grants exceeding $35 billion to nearly 60,000 organizations and more than 300,000 researchers, and the agency’s Feb. 7 decision to cap indirect awards was not the first time the government has tried to reign in costs.
The Clinton administration proposed a cap of 26% for indirect research costs, but it was rejected by Congress. President Barack Obama also considered reducing the limit, but dropped the idea in the face of widespread institutional opposition. And in 2017, during President Donald Trump’s first term, an across-the-board cap of 10% was proposed, but rejected by Congress.
Judge Kelley faulted the NIH for its failure to justify the rate reduction, saying it was arbitrary.
“The failure to provide any type of reasoning renders the rate change arbitrary and capricious,” she wrote. “In short, the notice fails to consider the impact the rate change would have on public health, which is the purpose of the entire regulatory regimen.”




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.